Ignite Creation Date:
2024-05-06 @ 6:12 PM
Last Modification Date:
2024-10-26 @ 2:44 PM
Study NCT ID:
NCT05586516
Status:
RECRUITING
Last Update Posted:
2024-06-10
First Post:
2022-10-13
Brief Title:
A Study to Assess an ATX Inhibitor IOA-289 in Patients With Metastatic Pancreatic Cancer
Sponsor:
iOnctura
Organization:
iOnctura
Study Overview
Official Title:
A Phase 1b Open Label Dose Escalation Study of IOA-289 an Orally Bioavailable Selective Autotaxin ENPP2 Inhibitor Alone and in Combination With GemcitabineNab-paclitaxel in Patients With Metastatic Pancreatic Cancer
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of study IOA-289-102 is to evaluate the safety and tolerability of escalating doses of IOA-289 in patients with metastatic pancreatic cancer in combination with standard chemotherapy consisting of gemcitabine and nab-paclitaxel Blood and tumour samples for PK and PD will be collected and assessments for determination of any clinical efficacy will be completed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None